A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
| 対象疾患 | Uveal Melanoma |
|---|---|
| 相 | 第2相 |
| スポンサー | Dana-Farber Cancer Institute |
| ステータス | 早期終了 |
| 参加者数 | 13 名 |
| 介入（薬剤） | BVD-523 |
| 開始日 | 2018年3月26日 |
| 完了日 | 2020年5月5日 |
| 結果公開日 | 2021年11月11日 |
概要
This research study is studying a targeted therapy called BVD-523 as a possible treatment for advanced uveal melanoma.
Overall Response Rate
| BVD-523 | 0 percentage of participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)